Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Self-expanding valve platforms are providing new and versatile options for transcatheter pulmonary valve replacement in patients with a large native or patched right ventricular outflow tract. We describe 4 cases of acute reintervention required after successful implantation of an Alterra Adaptive Prestent followed by SAPIEN S3.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12011174 | PMC |
| http://dx.doi.org/10.1016/j.jaccas.2024.102836 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Correction of Tricuspid Regurgitation in Pulmonary Arterial Hypertension.
JACC Case Rep
September 2025
Department of Cardiology, Monaldi Hospital, Naples, Italy. Electronic address:
Background: Pulmonary hypertension is a contraindication to correction of tricuspid regurgitation.
Case Summary: A 75-year-old Italian woman with previous episodes of right heart failure was diagnosed with World Health Organization (WHO) functional class IV pulmonary arterial hypertension (PAH) complicated by torrential tricuspid regurgitation. After 6 months of treatment with diuretic agents, macitentan, and tadalafil, she improved to WHO functional class III, with a pulmonary vascular resistance (PVR) decreasing from 5.
Spanish cardiac catheterization and coronary intervention registry. 34 official report of the Interventional Cardiology Association of the Spanish Society of Cardiology (1990-2024).
Rev Esp Cardiol (Engl Ed)
September 2025
Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, España; Servicio de Cardiología, Hospital Clínico de Santiago de Compostela, Santiago de Compostela, España.
Introduction And Objectives: This report presents the 2024 activity data from the Interventional Cardiology Association of the Spanish Society of Cardiology (ACI-SEC).
Methods: All interventional cardiology laboratories in Spain were invited to complete an online survey. Data analysis was conducted by an external company and then reviewed and presented by the ACI-SEC board.
Unravelling the "diabetes discrepancy": The presence of chronic complications is a hallmark of worse short-term outcomes in patients with diabetes mellitus after transcatheter aortic valve replacement.
Am J Med Sci
September 2025
The George Washington University School of Medicine and Health Sciences, Washington, DC.
Background: In transcatheter aortic valve replacement (TAVR), there is a notable "diabetes discrepancy", where worse/better/similar outcomes were all found for patients with diabetes mellitus (DM). Such divergent findings pose a challenge for clinicians to accurately assess the risks for DM patients undergoing TAVR. We hypothesized the presence of chronic complications could be linked to worse post-TAVR outcomes in DM patients.
View Article and Find Full Text PDFLate Survival and Self-reported Quality of Life in Octogenarians with Prior Sternotomy Undergoing Valvular Surgery.
Ann Thorac Surg
September 2025
Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota, USA. Electronic address:
Background: Recent advances in transcatheter valvular techniques often compete with open cardiac operations in managing high-risk patients with valvular disease, especially in the elderly. The present study assesses late survival and quality of life following valvular surgery in octogenarians with prior sternotomy.
Methods: We identified octogenarians who underwent cardiac valve reoperations between 2004 and 2023.
Efficacy of Cerebral Embolic Protection Device in Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis.
Catheter Cardiovasc Interv
September 2025
Oklahoma Heart Hospital, Oklahoma City, Oklahoma, USA.
Transcatheter aortic valve replacement (TAVR) is widely used to treat severe aortic stenosis; however, periprocedural stroke remains a significant concern. This systematic review and meta-analysis evaluate whether the use of cerebral embolic protection devices (CEPDs) during TAVR reduces the risk of stroke and other complications. To conduct a network meta-analysis of relevant trials to assess the efficacy of CEPDs currently used in TAVR.
View Article and Find Full Text PDF